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Zfp57a b s t r a c t
To maintain the self-renewal of embryonic stem (ES) cells, several core transcription factors, including
Oct3/4, STAT3, and Nanog, regulate the expression of their target genes. Zinc ﬁnger protein 57 (Zfp57)
is speciﬁcally expressed in self-renewing ES cells and its expression level is reduced upon ES cell differ-
entiation, suggesting that expression of this transcription factor is regulated by core transcription factors.
In the present study, we investigated whether Zfp57 expression is regulated by Nanog. Nanog overex-
pression resulted in the upregulation of Zfp57. On the other hand, knockdown of Nanog reduced the
expression level of Zfp57. In addition, we identiﬁed the Nanog-responsive region in the promoter of
the Zfp57 gene. These results suggest that Nanog is an upstream regulator of Zfp57. Moreover, Nanog
overexpression promoted the growth of ES cells in soft agar and this was suppressed by Zfp57 knock-
down, suggesting that the Nanog/Zfp57 pathway plays a central role in anchorage-independent growth
of ES cells. Interestingly, NANOG overexpression also led to the upregulation of ZFP57 in two human
tumor cell lines. Taken together, our results suggest that Nanog positively regulates Zfp57 expression
in multiple types of cells.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Embryonic stem (ES) cells are pluripotent stem cells that are
established from the inner cell mass of blastocysts. In the presence
of leukemia inhibitory factor (LIF), mouse ES cells remain in the
undifferentiated state and continue to self-renew indeﬁnitely.
Extensive studies have revealed the molecular mechanism under-
lying the regulation of ES cell self-renewal [1]. For example, it is
well-established that several transcription factors, such as Oct3/4
[2,3], Nanog [4,5], and STAT3 [6,7], play central roles in the
maintenance of self-renewal via the formation of core molecular
networks [8,9].Zinc ﬁnger protein 57 (Zfp57) is a transcription factor with sev-
eral zinc ﬁnger motifs and a Krüppel-associated box (KRAB)
domain. This transcription factor was originally cloned from a
mouse teratocarcinoma cell line as an undifferentiated cell-speciﬁc
gene [10]. Functional analysis using knockout mice revealed that
loss of the zygotic function of Zfp57 leads to partial lethality, while
eliminating both the maternal and zygotic functions of Zfp57
results in complete embryonic lethality [11]. The ZFP57 protein
recruits KRAB-associated protein 1 (KAP1), a scaffold molecule
for heterochromatin-inducing factors, to multiple imprinting con-
trol regions, and thus participates in regulation of genome imprint-
ing [11–13]. Although the successful establishment of Zfp57-null
ES cells indicates that Zfp57 is dispensable for the maintenance
of ES cell self-renewal [14], we recently reported that this tran-
scription factor is involved in the anchorage-independent growth
of ES cells [15]. In addition, ZFP57 can stimulate anchorage-inde-
pendent growth of the mouse immortal ﬁbroblast cell line NIH3T3
and promote tumor formation of human ﬁbrosarcoma HT1080
cells in nude mice. Furthermore, our immunohistochemical analy-
sis revealed that ZFP57 is overexpressed in several tumor tissues.
Similarly, Cirillo et al. recently showed that increased expression
818 Y. Yamaguchi et al. / Biochemical and Biophysical Research Communications 453 (2014) 817–820of ZFP57 is associated with high-grade glioblastoma [16]. These
ﬁndings suggest that ZFP57 can function as an oncogene in some
types of cancer. In addition, mutations in the ZFP57 gene can
reportedly cause transient neonatal diabetes mellitus type 1 [17].
Among mouse ES cells, expression of Zfp57 is restricted to those
cells in an undifferentiated state and is lost following LIF removal
[14], suggesting that expression of Zfp57 is regulated by self-
renewal-related transcription factors. Zfp57 is a downstream mol-
ecule of STAT3 and Oct3/4 [14]. However, the possible involvement
of Nanog, another self-renewal transcription factor, in Zfp57 regu-
lation has not been investigated. In this study, we explored this
possibility and found that Nanog also regulates Zfp57 expression
in mouse ES cells. In addition, we found that activation of the
Nanog/Zfp57 axis promotes anchorage-independent growth of ES








































Fig. 1. Nanog upregulates Zfp57 expression in ES cells. (A) Overexpression of Nanog
leads to upregulation of Zfp57. E14 cells were transfected with Nanog and subjected
to RT-PCR analysis using the primers listed in Table S1. (B) Nanog knockdown
results in downregulation of Zfp57. After transfection with an expression vector for
negative control miRNA, Nanog miRNA(582), or Nanog miRNA(710), E14 cells were
subjected to RT-PCR analysis. In both panels, data are representative of three
independent experiments. G3PDH, glyceraldehyde 3-phosphate dehydrogenase.2. Materials and methods
2.1. Cell culture
The mouse ES cell line E14 (E14tg2a) and the human colorectal
adenocarcinoma cell line HT29 were obtained from the American
Type Culture Collection. The human ﬁbrosarcoma cell line
HT1080 was obtained from the Health Science Research Resources
Bank (Osaka, Japan). E14 and HT1080 cells were cultured as
described previously [15]. HT29 cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium (Nacalai Tesque, Kyoto, Japan) supple-
mented with 10% fetal bovine serum (Biowest, Nuaillé, France).
2.2. Plasmid construction
Construction of the mammalian expression vectors, pCAG-IP
and pCAGIP-myc-Nanog, has been described previously [18]. A
DNA fragment containing emerald green ﬂuorescent protein
(EmGFP) cDNA and control microRNA (miRNA) was transferred
from pGW/EmGFP-control miRNA [15] to pCAG-IP and pCAG-IH3
[15] to obtain pCAGIP-EmGFP-control miRNA and pCAGIH3-
EmGFP-control miRNA, respectively. The coding region of myc-
tagged human NANOG was inserted into pEBM-CAGIP [15] to
obtain pEBM-CAGIP-myc-hNanog. Expression vectors for artiﬁcial
miRNAs against Nanog, namely, pCAGIP-EmGFP-Nanog(582) and
-Nanog(710), were constructed by replacing the miRNA of pCA-
GIP-EmGFP-control miRNA with 50-ctg TTA TAG CTC AGG TTC
AGA ATG GTT TTG GCC ACT GAC TGA CCA TTC TGA CTG AGC TAT
AAc ag-30 and 50-ctg AAT GGA TGC TGG GAT ACT CCA GTT TTG
GCC ACT GAC TGA CTG GAG TAT CAG CAT CCA TTc ag-30, respec-
tively. Similarly, expression vectors for artiﬁcial miRNA against
Zfp57, namely, pCAGIH3-EmGFP-Zfp57(1008) and -Zfp57(1082),
were obtained by replacing the miRNA of pCAGIH3-EmGFP-control
miRNA with 50-ctg TAA ATG AGC ACG TCG GTG ACG GTT TTG GCC
ACT GAC TGA CCG TCA CCG GTG CTC ATT TAc ag-30 and 50-ctg TTC
AGG TGA CGG TTG ACC TCA GTT TTG GCC ACT GAC TGA CTG AGG
TCA CGT CAC CTG AAc ag-30, respectively. Using genomic DNA iso-
lated from the mouse ES cell line A3-1 [19] as a template, a 289-bp
fragment of the Zfp57 promoter (positions210 to +79) was ampli-
ﬁed by PCR with the primers 50-GGT ACC AAG GAA TTA CGG AAA
TTG AGT C-30 and 50-CTC GAG AAG TCA GGA ATC CGC TAC TTT
G-30. The ampliﬁed fragment was then inserted into pGL4.10 (Pro-
mega, Madison, WI) to obtain pGL4-zfp57 (210/+79).
2.3. RT-PCR analysis
Total RNA was isolated with Sepasol-RNA I Super G (Nacalai
Tesque) and converted to cDNA using Revertra Ace (Toyobo, Osaka,Japan) and oligo(dT)12–18 primers (Nippon Gene, Tokyo, Japan). The
primer sets used for PCR analysis are listed in Supplementary
Table S1. Glyceraldehyde 3-phosphate dehydrogenase (G3PDH)
was used as an internal control.2.4. Reporter assay and soft agar assay
For the reporter assay, cells were cultured for 2 days after trans-
fection and then harvested to prepare a cell lysate. The luciferase
activity of each lysate was measured using a dual luciferase assay
system (Promega) according to the manufacturer’s protocol.
The soft agar assay was basically performed as described previ-
ously [15]. Brieﬂy, 300 cells were seeded into culture medium con-
taining 0.5% agarose in 6-cm Petri dishes (Kord Products, Ontario,
Canada). Cells were then cultured for 1–2 weeks and viable colo-
nies were stained with 3-(4,5-di-methylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (Nacalai Tesque).3. Results
3.1. Nanog upregulates Zfp57 expression in ES cells
To determine if Nanog is an upstream regulator of Zfp57 in
mouse ES cells, we ﬁrst examined the effect of Nanog overexpres-
sion on the expression level of Zfp57. When Nanog was overex-
pressed in ES cells, expression of Zfp57 was upregulated
(Fig. 1A), suggesting that Zfp57 is a downstream molecule of
Nanog. To conﬁrm this, we suppressed Nanog expression using
two artiﬁcial microRNAs (miRNAs) (Supplementary Fig. S1). Nanog
knockdown resulted in the downregulation of Zfp57 (Fig. 1B),
which corresponds well with the results of a previous microarray
analysis [20]. These results suggest that Nanog positively regulates
Zfp57 expression.
To search for a Nanog-responsive region in the Zfp57 gene, we
preliminarily cloned several regions from 0 to 6 kb upstream of
the transcription start site and measured their enhancer/promoter
activities. A region of approximately 300 bp (210 to +79) exhib-
ited high promoter activity (Fig. 2A). Furthermore, Nanog overex-
pression increased the promoter activity of this region (Fig. 2B
and Supplementary Fig. S2), while Nanog knockdown decreased
the promoter activity of this region (Fig. 2C). These results suggest





























































Fig. 2. Identiﬁcation of a Nanog-responsive region in the Zfp57 promoter. (A)
Promoter activity of the 50-ﬂanking region (210/+79) of the Zfp57 gene in ES cells.
E14 cells were transfected with pGL4.10 or pGL4-zfp57(210/+79) and luciferase
activity was examined. (B) Nanog overexpression increases the promoter activity of
the Zfp57 gene. E14 cells were transfected with pCAG-IP (control) or pCAGIP-myc-
Nanog (Nanog) together with pGL4-zfp57(210/+79) and subjected to the reporter
assay. (C) Nanog knockdown decreases the promoter activity of the Zfp57 gene.
After transfection with pGL4-zfp57(210/+79) and expression vectors for control or
Nanog-targeting microRNAs, E14 cells were subjected to the reporter assay. In all














































Fig. 3. Role of Zfp57 as a downstream molecule of Nanog. (A) Nanog promotes
anchorage-independent growth of ES cells. E14 cells were transfected with or
without Nanog and cultured for more than 1 week in the presence of puromycin.
Puromycin-resistant E14 cells were pooled and subjected to the soft agar assay. (B)
Zfp57 knockdown inhibits Nanog-enhanced anchorage-independent growth of ES
cells. Nanog-overexpressing E14 cells were transfected with expression vectors for
control or Zfp57-targeting miRNAs, cultured in the presence of hygromycin, and
subjected to the soft agar assay. In both panels, bars represent the mean and error






















Fig. 4. NANOG overexpression increases expression of ZFP57 in HT1080 (A) and
HT29 cells (B). After transfection with or without NANOG, cells were cultured in the
presence of puromycin and resistant clones were pooled and subjected to RT-PCR
analysis. In both panels, data are representative of three independent experiments.
G3PDH, glyceraldehyde 3-phosphate dehydrogenase.
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growth of ES cells
We identiﬁed Zfp57 as a downstreammolecule of Nanog; there-
fore, we next examined the biological role of the Nanog/Zfp57
pathway in ES cells. We previously reported that Zfp57 is involved
in anchorage-independent growth of ES cells [15]. Nanog is
involved in the anchorage-independent growth of several types
of cells [21–23]. These observations raise the possibility that the
Nanog/Zfp57 axis is involved in the anchorage-independent
growth of ES cells. To explore this possibility, we ﬁrst investigated
whether Nanog can promote anchorage-independent growth of ES
cells. When Nanog was overexpressed in ES cells, the number of
viable colonies in soft agar was increased, suggesting that Nanog
promotes the growth of ES cells in soft agar (Fig. 3A and Supple-
mentary Fig. S3A). On the other hand, when the expression level
of Zfp57 was reduced in Nanog-overexpressing ES cells using arti-
ﬁcial miRNAs, the number of viable colonies decreased (Fig. 3B and
Supplementary Fig. S3B and C), suggesting that Zfp57 is involved in
Nanog-promoted anchorage-independent growth of ES cells. These
results suggest that the Nanog/Zfp57 pathway controls anchorage-
independent growth of ES cells.3.3. NANOG upregulates ZFP57 expression in human cancer cells
To determine whether regulation of Zfp57 expression by Nanog
is restricted to ES cells, we examined the effect of NANOG overex-
pression on the expression level of ZFP57 in two cancer cell lines,
HT29 and HT1080, which are derived from human colorectal can-
cer and ﬁbrosarcoma, respectively. In both cancer cell lines,
NANOG overexpression increased the expression level of ZFP57
(Fig. 4). These results suggest that Nanog upregulates Zfp57 not
only in mouse ES cells but also in human cancer cell lines.4. Discussion
In this study, we demonstrated that expression of Zfp57 is pos-
itively regulated by Nanog in ES cells. We also found that Zfp57 is
involved in Nanog-promoted anchorage-independent growth of ES
cells, suggesting that the Nanog/Zfp57 pathway plays an important
role in this cell growth. In addition, we found that NANOG also reg-
ulates ZFP57 expression in human tumor cells.
We identiﬁed Zfp57 as a downstream molecule of Nanog. In
addition, we identiﬁed a Nanog-responsive region upstream of
the Zfp57 gene. However, we do not know whether Nanog binds
directly to this region to regulate Zfp57 expression. To address this,
we performed a chromatin immunoprecipitation assay; however,
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with this region thus far. It is therefore possible that Nanog regu-
lates Zfp57 expression indirectly via another transcription
factor(s).
Although we showed that the Nanog/Zfp57 pathway promotes
anchorage-independent growth of ES cells, the underlying molecu-
lar mechanism remains unclear. We previously demonstrated that
ZFP57 promotes the anchorage-independent growth of human
ﬁbrosarcoma cells by upregulating expression of insulin-like
growth factor 2 (IGF2) [15]. However, Zfp57 knockout did not sig-
niﬁcantly reduce the expression of this growth factor in ES cells
(data not shown), suggesting that Zfp57 does not upregulate
IGF2 expression in these cells. Therefore, the Nanog/Zfp57 pathway
may promote anchorage-independent growth of ES cells in an
IGF2-independent manner.
NANOG upregulated ZFP57 expression in HT1080 cells in the
current study. Additionally, we previously reported that NANOG
and ZFP57 both promote anchorage-independent growth of
HT1080 cells [15]. These ﬁndings suggest that NANOG promotes
anchorage-independent growth of HT1080 cells via upregulating
ZFP57. NANOG plays an important role in tumorigenesis [22,24]
and NANOG overexpression is often associated with poor prognosis
in several types of cancer [24–27]. ZFP57 is overexpressed in sev-
eral types of tumor tissues [15,16]; therefore, it is possible that
the NANOG/ZFP57 axis plays a central role in tumorigenesis and
metastasis of several types of cancer. Further investigation of the
NANOG/ZFP57 pathway would help to better understand the role
of stem cell factors in oncogenesis.
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